Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Real-world data showed that atezolizumab provided a benefit and was safe in patients with platinum-ineligible mUC and high comorbidities/functional status.

First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC 

Tanya Gupta, MD, highlights the utility of adjuvant CDK4/6 and PARP inhibitors in patients with HR-positive, HER2-negative breast cancer.

Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer

Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer

Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.

Abemaciclib/Hormonal Therapy Combo Yields Clinical Activity in LGSOC/EEC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

 team as an assistant editor in 2025 after previously working on the 

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Tanya Gupta, MD, details FDA-approved CDK4/6 inhibitors and considerations for selecting treatment in HR-positive, HER2-negative metastatic breast cancer. 

Selection of Frontline CDK4/6 Inhibitors Hinges on Patient Health Status in HR+/HER2– Metastatic Breast Cancer

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new genetic therapy to treat glioblastoma.

New Grant Funds First-of-Its-Kind Gene Therapy to Treat Aggressive Brain Cancer

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

Bioengineered Bone Marrow Model Reveals Potential New Strategies for Osteosarcoma Metastasis Control

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant R/R Follicular Lymphoma 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

1rem

primary

View

Updates in CRC: Applying Evidence to Clinical Practice

Clinical

Video Series

Patient Centered Approach: Important Patient Counseling Points regarding ctDNA results in CRC

Videos

Panelists review a patient case of a 45 year old man with high-risk T4N0 resected CRC.

Starting with a Patient Case: 45yM high-risk T4N0 resected CRC - What are next steps?

Panelists discuss important patient counseling points regarding ctDNA results in colorectal cancer (CRC), focusing on how to communicate the implications of these results for treatment decisions, prognosis, and personalized care planning.





Panelists discuss how the CIRCULATE study's GALAXY results demonstrate the potential impact of circulating tumor DNA analysis in guiding adjuvant therapy decisions for stage II colon cancer patients, though further validation is needed before widespread clinical implementation.




Expert Perspectives: GALAXY Results from CIRUCLATE study - Is it Practice Changing?

Panelists discuss how patterns of ctDNA clearance in resected colorectal cancer patients - whether transient or sustained - can inform prognosis, guide treatment decisions, and predict disease recurrence risk.



Understanding ctDNA in Resected CRC: Transient vs. Sustained Clearance & Clinical Implications

Panelists discuss how to navigate real-world challenges in implementing ctDNA testing for colorectal cancer patients, including issues of test accessibility, result interpretation, insurance coverage, and integration into clinical workflows.


Practical Considerations: Complexities with Utilizing ctDNA in CRC in the Real-World Practice Setting

Panelists discuss how the NICHE-2 trial results demonstrate the potential benefits and implementation of neoadjuvant immunotherapy in patients with dMMR colon cancer, highlighting pathologic response rates and implications for treatment sequencing.

Exploring the NICHE-2 Trial: Neoadjuvant Immunotherapy in dMMR Colon Cancer

Panelists discuss how Minimal Residual Disease (MRD) and circulating tumor DNA (ctDNA) testing are revolutionizing colon cancer management through improved risk stratification, treatment selection, and surveillance strategies.

Final Insights: Emerging role of MRD and ctDNA testing in Colon Cancer

OncLive Insights

Patient Centered Approach: Important Patient Counseling Points regarding ctDNA results in CRC

EP: 1.Starting with a Patient Case: 45yM high-risk T4N0 resected CRC - What are next steps?

EP: 2.Patient Centered Approach: Important Patient Counseling Points regarding ctDNA results in CRC

EP: 3.Expert Perspectives: GALAXY Results from CIRUCLATE study - Is it Practice Changing?

EP: 4.Understanding ctDNA in Resected CRC: Transient vs. Sustained Clearance & Clinical Implications

EP: 5.Practical Considerations: Complexities with Utilizing ctDNA in CRC in the Real-World Practice Setting

EP: 6.Exploring the NICHE-2 Trial: Neoadjuvant Immunotherapy in dMMR Colon Cancer

EP: 7.Final Insights: Emerging role of MRD and ctDNA testing in Colon Cancer

Newsletter

Latest Conference Coverage